Nexalin Technology (NXL) Cash & Equivalents (2021 - 2026)

Nexalin Technology has reported Cash & Equivalents for 6 years, with the latest figure at $1.0 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 81.26% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $1.0 million, a 81.26% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, up 5.61% from the prior year.
• Cash & Equivalents was $1.0 million for Q2 2026 at Nexalin Technology, down from $1.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $7.9 million in Q3 2022, with the low at $848796.0 in Q2 2024.
• Average Cash & Equivalents over 5 years is $3.5 million, with a median of $3.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents soared 932.25% in 2022, then slumped 81.26% in 2026.
• Over 5 years, Cash & Equivalents stood at $6.8 million in 2022, then slumped by 65.33% to $2.4 million in 2023, then gained by 22.69% to $2.9 million in 2024, then grew by 5.61% to $3.1 million in 2025, then tumbled by 67.25% to $1.0 million in 2026.
• The last three Cash & Equivalents figures came in at $1.0 million (Q2 2026), $1.5 million (Q1 2026), and $3.1 million (Q4 2025), per Business Quant data.